Guest Column | September 25, 2014

Screening Prospective CROs: What Are Their Data Capabilities?

Clinical development is the most costly aspect of getting a drug, medical device or diagnostic to market.  Previously priced at $1.3 billion, getting a product approved is now estimated to cost as much as $5 billion. If you entrust management of your clinical trial to a CRO, what criteria should you look for in a partner to ensure the most reliable results with the greatest efficiencies at the most affordable price?

One major issue for sponsors partnering with CROs for analytic services is the ability to directly access and retrieve their raw data, which may only be accessible from the CRO's data warehouse, source systems, or down-stream analysis platforms.  Requesting and receiving both ad-hoc/custom and periodic standard reports from their CRO can potentially result in critical time lags and inefficiency for program, country, study and data managers, as well as for clinical research associates, investigators, clinicians and safety officers. 

access the Guest Column!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader